Literature DB >> 19210910

Neuralgic amyotrophy.

Lenay Santana1, Amparo Gutierrez.   

Abstract

Neuralgic amyotrophy has a broad variety of clinical manifestations. Although it was initially thought to be a plexopathy, its diverse presentation can include isolated sensory nerves or even cranial nerves. Although neuralgic amyotrophy is usually a benign condition with a good recovery, pain can be a disabling feature. NSAIDs and short-term narcotics are appropriate treatments. There is lack of evidence whether the use of corticosteroids has an impact on the duration of the disease or the neuropathic pain. However, given the few adverse effects in a selective population and low cost, short-term steroids can be an option for the treatment of these patients.

Entities:  

Year:  2009        PMID: 19210910     DOI: 10.1007/s11940-009-0011-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  19 in total

1.  The variations of neuralgic amyotrophy.

Authors:  J D England
Journal:  Muscle Nerve       Date:  1999-04       Impact factor: 3.217

2.  The clinical spectrum of neuralgic amyotrophy in 246 cases.

Authors:  Nens van Alfen; Baziel G M van Engelen
Journal:  Brain       Date:  2005-12-21       Impact factor: 13.501

3.  Neuralgic amyotrophy; the shoulder-girdle syndrome.

Authors:  M J PARSONAGE; J W A TURNER
Journal:  Lancet       Date:  1948-06-26       Impact factor: 79.321

Review 4.  Brachial neuritis.

Authors:  E C McCarty; P Tsairis; R F Warren
Journal:  Clin Orthop Relat Res       Date:  1999-11       Impact factor: 4.176

5.  The flexion-adduction sign in neuralgic amyotrophy.

Authors:  S G Waxman
Journal:  Neurology       Date:  1979-09       Impact factor: 9.910

6.  MRI findings of 26 patients with Parsonage-Turner syndrome.

Authors:  Richard E Scalf; Doris E Wenger; Matthew A Frick; Jayawant N Mandrekar; Mark C Adkins
Journal:  AJR Am J Roentgenol       Date:  2007-07       Impact factor: 3.959

7.  Neuralgic amyotrophy (paralytic brachial neuritis); with special reference to prognosis.

Authors:  J W A TURNER; M J PARSONAGE
Journal:  Lancet       Date:  1957-08-03       Impact factor: 79.321

8.  Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy.

Authors:  F J Vriesendorp; G S Dmytrenko; T Dietrich; C L Koski
Journal:  Arch Neurol       Date:  1993-12

9.  Neuralgic amyotrophy: variable expression in 40 patients.

Authors:  A Cruz-Martínez; M Barrio; J Arpa
Journal:  J Peripher Nerv Syst       Date:  2002-09       Impact factor: 3.494

10.  Neuralgic amyotrophy: clinical features and diagnostic evaluation.

Authors:  D I Rubin
Journal:  Neurologist       Date:  2001-11       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.